Development and Statistical Optimization of Solid Lipid Nanoparticles of Simvastatin by Using 23 Full-Factorial Design

The objective of this study was to develop solid lipid nanoparticles (SLNs) of simvastatin and to optimize it for independent variables (amount of glycerol monostearate, concentration of poloxamer, and volume of isopropyl alcohol) in order to achieve desired particle size with maximum percent entrapment efficiency (% EE) and percent cumulative drug release (% CDR). To achieve our goal, eight formulations (F1–F8) of SLNs were prepared by solvent injection technique and optimized by 23 full-factorial design. The design was validated by extra design checkpoint formulation (F9), and the possible interactions between independent variables were studied. The responses of the design were analyzed using Design Expert 7.1.6. (Stat-Ease, Inc, USA), and the analytical tools of software were used to draw Pareto charts and response surface plots. On the basis of software analysis, formulation F10 with a desirability factor of 0.611 was selected as optimized formulation and was evaluated for the independent parameters. Optimized formulation showed particle size of 258.5 nm, % EE of 75.81%, with of 82.67% CDR after 55 h. The release kinetics of the optimized formulation best fitted the Higuchi model, and the recrystallization index of optimized formulation was found to be 65.51%.

[1]  Vemula Satyanarayana,et al.  Preparation, characterization, and in vitro and in vivo evaluation of lovastatin solid lipid nanoparticles , 2007, AAPS PharmSciTech.

[2]  Louis S. Goodman,et al.  The Pharmacological Basis of Therapeutics. , 1941 .

[3]  Y. Nishioka,et al.  Lymphatic targeting with nanoparticulate system. , 2001, Advanced drug delivery reviews.

[4]  K. Derakhshandeh,et al.  Encapsulation of 9-nitrocamptothecin, a novel anticancer drug, in biodegradable nanoparticles: factorial design, characterization and release kinetics. , 2007, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[5]  Michael Montagne,et al.  Pharmaceutical Statistics: Practical and Clinical Applications , 1985 .

[6]  R. Müller,et al.  Peptide-loaded solid lipid nanoparticles (SLN): Influence of production parameters , 1997 .

[7]  T. Tan,et al.  Preparation of oridonin-loaded solid lipid nanoparticles and studies on them in vitro and in vivo , 2006 .

[8]  Jia-bi Zhu,et al.  Body Distribution of Camptothecin Solid Lipid Nanoparticles After Oral Administration , 1999, Pharmaceutical Research.

[9]  F. Hu,et al.  Glyceryl Monooleate/Poloxamer 407 Cubic Nanoparticles as Oral Drug Delivery Systems: I. In Vitro Evaluation and Enhanced Oral Bioavailability of the Poorly Water-Soluble Drug Simvastatin , 2009, AAPS PharmSciTech.

[10]  R. Müller,et al.  Cytotoxicity of magnetite-loaded polylactide, polylactide/glycolide particles and solid lipid nanoparticles , 1996 .

[11]  K. Mäder,et al.  Solid lipid nanoparticles: production, characterization and applications. , 2001, Advanced drug delivery reviews.

[12]  M. Schubert,et al.  Solvent injection as a new approach for manufacturing lipid nanoparticles--evaluation of the method and process parameters. , 2003, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[13]  V. Venkateswarlu,et al.  Solid lipid nanoparticles as drug delivery systems. , 2005, Methods and findings in experimental and clinical pharmacology.

[14]  S. B. Tiwari,et al.  Formulation optimization for the nanoparticles-in-microsphere hybrid oral delivery system using factorial design. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[15]  Heike Bunjes,et al.  Incorporation of the Model Drug Ubidecarenone into Solid Lipid Nanoparticles , 2001, Pharmaceutical Research.

[16]  R. Murthy,et al.  Etoposide-loaded nanoparticles made from glyceride lipids: Formulation, characterization, in vitro drug release, and stability evaluation , 2005, AAPS PharmSciTech.

[17]  R. Gurny,et al.  New approach for the preparation of nanoparticles by an emulsification-diffusion method , 1995 .

[18]  Asuman Bozkir,et al.  Formulation and investigation of 5-FU nanoparticles with factorial design-based studies. , 2005, Farmaco.

[19]  Hong Yuan,et al.  Preparation of solid lipid nanoparticles with clobetasol propionate by a novel solvent diffusion method in aqueous system and physicochemical characterization. , 2002, International journal of pharmaceutics.